Xisomab 3G3 for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Receiving Chemotherapy
A Phase II Study of Xisomab 3G3, a Monoclonal Antibody Preventing the Activation of FXI by FXIIa, for the Prophylaxis of Catheter-Associated Thrombosis
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Terminated
Insufficient accrual rate
Other terminated trials from National Heart, Lung, and Blood Institute (NHLBI)
- Fracture of Radius and Ulna · Phase NA · Feb 2026
- Asthma · Aug 2025
- Acute Respiratory Failure · Phase PHASE3 · Jul 2025
- Asthma in Children · Phase NA · Jul 2025
- Aortic Valve Stenosis · Phase NA · Dec 2024
See all terminations from National Heart, Lung, and Blood Institute (NHLBI)
Listed as NCT04465760, this PHASE2 trial focuses on Lymphoma and Malignant Solid Neoplasm and remains terminated or withdrawn. Sponsored by National Heart, Lung, and Blood Institute (NHLBI), it has been updated 10 times since 2021, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Feb 2024 — Jul 2024 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Nov 2022 — Feb 2024 [monthly]
Recruiting PHASE2
-
Apr 2022 — Nov 2022 [monthly]
Recruiting PHASE2
▶ Show 5 earlier versions
-
Sep 2021 — Apr 2022 [monthly]
Recruiting PHASE2
-
Apr 2021 — Sep 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jan 2021 — Apr 2021 [monthly]
Not Yet Recruiting PHASE2
-
Oct 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE2
-
Aug 2020 — Oct 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- National Heart, Lung, and Blood Institute (NHLBI)
- OHSU Knight Cancer Institute
- Oregon Health and Science University
For direct contact, visit the study record on ClinicalTrials.gov .